Shares of Elan Corp. (NYSE: ELN) surged $2.25 to close at $14.07 as bargain hunters snapped up the biotech. The stock price plunged in recent weeks after reporting mixed results for its Alzheimer's treatment and the development of a rare and possibly fatal brain condition in two patients using the company's multiple sclerosis treatment Tysabri.
Bargain Hunters Lift Elan
August 15, 2008 at 18:38 PM EDT
